Category Archives: Public Policy

Latest From Public Policy

Is the FTC well-suited to take on IP/Patent policy?

On December 5, 2008 the Federal Trade Commission held the first in a series of hearings entitled: The Evolving IP Marketplace. According to the FTC, the hearings are intended to examine changes in intellectual property law and patent-related business models since the FTC issued its October 2003 report, entitled To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy A Report by the Federal Trade Commission. December 5th’s hearing featured CAFC Chief Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO IP Counsels’ Committee Conference Now Open for Non-BIO Member Company Attendance

Since 2002, BIO’s IP Counsels’ Committee Conference was a private event where BIO members learned about the hottest topics in the industry: newly-introduced legislation on Patent Reform, draft BIO comments to the Patent & Trademark Office, experiences from fellow member companies and universities, all under the guise of a “fun” 3-day Conference & Meeting. Well, the results are in: the Conference has always been fun, because of the savvy planning of BIO staffers who incorporate Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Welcome!

Welcome to PatentlyBIOtech, BIO’s newest (and prettiest) blog. The blog’s all about intellectual property, technology transfer, biotechnology, gene patenting, global health, economic growth, sustainability, green jobs, you name it… and we’ll help you along the way! I wanted to share some quotations get us in the mood… “Somewhere, something incredible is waiting to be known.” Carl Sagan “Knowing is not enough; we must apply!” Goethe “I was brought up to believe that the only thing worth Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

From the Hill to the Street: Examining Policy Issues in Biotech

Without a supportive legislative and regulatory environment, biotech companies cannot raise the funds necessary to get a product to market.  The panelists explored the pressing policy issues which could have a significant impact on the industry, from the creation of a pathway for the approval of follow-on biologics, patent reform, comparative effectiveness and the implementation of the Food and Drug Administration Amendments Act (FDAAA) which was signed into law last year.  The panelists also discussed Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: